Alembic Pharma gets tentative USFDA nod for drug treating hyperuricemia patients

New Delhi: Alembic Pharmaceuticals has received tentative approval from the US health regulator for Febuxostat tablets used for treatment of hyperuricemia in patients of gout.

Pharma1

"The company has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Febuxostat tablets, 40 mg and 80 mg," Alembic Pharmaceuticals said in a BSE filing.

The product is therapeutic equivalent to the reference listed drug Uloric tablets, 40 mg, 80 mg of Takeda Pharmaceuticals USA Inc, it added.

Alembic Pharmaceuticals said it has settled the case with Takeda and will launch its generic as per the terms of settlement.

The tablets, indicated for chronic management of hyperuricemia in patients of gout, has an estimated market size of $430 million for 12 months to December 2015.

The company has 48 ANDA approvals (43 final and 5 tentative from the USFDA.

Alembic stock was trading 0.57 per cent up at Rs 582.75 in the morning trade on BSE.


Updated Date: Jul 05, 2016 12:41 PM

Also Watch

IPL 2018: Royal Challengers Bangalore eye revival against Chennai Super Kings as 'Cauvery Derby' comes back to life
  • Thursday, April 26, 2018 In the Kanjarbhat community, a campaign against 'virginity tests' is slowly gaining ground
  • Tuesday, April 24, 2018 It's A Wrap: Beyond the Clouds stars Ishaan Khatter, Malavika Mohanan in conversation with Parul Sharma
  • Monday, April 9, 2018 48 hours with Huawei P20 Pro: Triple camera offering is set to redefine smartphone imaging
  • Monday, April 16, 2018 Rajyavardhan Singh Rathore interview: Sports can't be anyone's fiefdom, we need an ecosystem to nurture raw talent

Also See